דילוג לניווט ראשי דילוג לחיפוש דילוג לתוכן הראשי

Safety of the newer class of opioid antagonists in pregnancy

  • Shirley Poon
  • , Anna Pupco
  • , Gideon Koren
  • , Pina Bozzo

פרסום מחקרי: פרסום בכתב עתסקירהביקורת עמיתים

10 ציטוטים ‏(Scopus)

תקציר

Question: I have a patient recently confirmed to be 6 weeks pregnant. For the past 6 months she has been treated for an opioid addiction with buprenorphine-naloxone combination. Should I be concerned about her exposure to this drug combination up to this point of the pregnancy? Should I switch her medication to methadone now that she is pregnant? Answer: The limited data on buprenorphine exposure during pregnancy show no increased risk of adverse outcomes in the newborn. There are limited data on naloxone exposure during pregnancy; however, oral use is not expected to be associated with an increased risk of adverse pregnancy outcomes. Physicians treating pregnant women or women who become pregnant while they are stable taking buprenorphine-naloxone treatment are advised to continue this treatment but to consider transition to buprenorphine monotherapy.

כותר מתורגם של התרומהSafety of the newer class of opioid antagonists in pregnancy
שפה מקוריתאנגלית
עמודים (מ-עד)631-632+E348-E349
כתב עתCanadian Family Physician
כרך60
מספר גיליון7
סטטוס פרסוםפורסם - יולי 2014

טביעת אצבע

להלן מוצגים תחומי המחקר של הפרסום 'Safety of the newer class of opioid antagonists in pregnancy'. יחד הם יוצרים טביעת אצבע ייחודית.

פורמט ציטוט ביבליוגרפי